Friends of Cancer Research Virtual Meeting
The Next Generation of Cellular Therapies:
Opportunities to Accelerate Development
Wednesday, March 8, 2023
12:00PM EST – 1:00PM EST
Thank you to all that attended!
Click HERE to Watch the Full Meeting
Meeting Discussion Document
Presentation 1 Slides Presentation 2 Slides
Please register here for the next meeting in this series on May 22nd,
The Next Generation of Cellular Therapies: A Blueprint to Accelerate Development
Friends of Cancer Research (Friends) is proud to announce a new virtual meeting, The Next Generation of Cellular Therapies: Opportunities to Accelerate Development, the first in a two-meeting series focusing on cell and gene therapies.
This meeting will bring together experts in the field to explore strategies to advance the development of the next generation of cell and gene therapy products by leveraging scientific and clinical advancements to inform regulatory policy. Panel discussions will elucidate components of a regulatory framework that enables streamlined evidence generation across different versions of cell therapy products and brings innovative therapies to patients quickly.
This meeting builds on Friends’ previous work on Cell & Gene Therapies, and is the first of two meetings in 2023 to explore next steps in the field. Following this virtual meeting to introduce the topic, we will bring stakeholders together for a hybrid meeting in Washington, DC on May 22 to further discuss implementation of these strategies and a streamlined regulatory framework. Click Here for more information.
Register for the meeting above and scroll through below for the current draft agenda.
12:00PM – Welcoming Remarks
12:02PM – Keynote — Peter Marks, Director, CBER, U.S. FDA
12:10PM – Presentation 1: Academic Institution Experience — Julie Jadlowsky, University of Pennsylvania
12:20PM – Presentation 2: Industry Experience: Yescarta & Tecartus Case Study — Jonathan Jazayeria, Kite, A Gilead Company
12:30PM – Panel Discussion
- Michael Kalos, Next Pillar Consulting — Moderator
- Marc Better, Pharmefex
- Julie Jadlowsky, University of Pennsylvania
- Jonathan Jazayeri, Kite, a Gilead Company
- Ingrid Markovic, U.S. FDA
12:58PM – Concluding Remarks
1:00PM – Meeting Adjournment